Insights

More Articles Back to Article

Adaptimmune's synovial sarcoma drug gains PRIME status

The European Medicines Agency granted PRIME status to Adaptimmune's treatment for synovial sarcoma, ADP-A2M4. The tag will Adaptimmune access to additional support and guidance from the EMA to facilitate the drug's development. PharmaTimes online (UK) (7/28)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!